AngioDynamics, Inc.

NasdaqGS:ANGO Voorraadrapport

Marktkapitalisatie: US$273.1m

AngioDynamics Beheer

Beheer criteriumcontroles 2/4

De CEO AngioDynamics is Jim Clemmer, benoemd in Apr2016, heeft een ambtstermijn van 8.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.01M, bestaande uit 15.6% salaris en 84.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.17% van de aandelen van het bedrijf, ter waarde $ 3.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.4 jaar en 8.7 jaar.

Belangrijke informatie

Jim Clemmer

Algemeen directeur

US$5.0m

Totale compensatie

Percentage CEO-salaris15.6%
Dienstverband CEO8.6yrs
Eigendom CEO1.2%
Management gemiddelde ambtstermijn6.4yrs
Gemiddelde ambtstermijn bestuur8.7yrs

Recente managementupdates

Recent updates

AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Jul 19
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

Jul 18
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified

AngioDynamics: A Story To Monitor

May 14

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 09

AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

Apr 06
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry

AngioDynamics: Restructuring Initiative May Not Go Far Enough

Jan 14

AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Oct 12
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

Mar 31
AngioDynamics (NASDAQ:ANGO) Is Carrying A Fair Bit Of Debt

AngioDynamics Non-GAAP EPS of -$0.06 misses by $0.04, revenue of $81.5M misses by $1.93M, reaffirms FY guidance

Oct 06

AngioDynamics: Lack Of Upside Capture Remains, Continue To Hold

Sep 29

Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

Sep 02
Is AngioDynamics (NASDAQ:ANGO) Using Debt In A Risky Way?

AngioDynamics Non-GAAP EPS of $0.01 in-line, revenue of $87M beats by $4.09M

Jul 12

Analyse CEO-vergoeding

Hoe is Jim Clemmer's beloning veranderd ten opzichte van AngioDynamics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Aug 31 2024n/an/a

-US$243m

May 31 2024US$5mUS$783k

-US$184m

Feb 29 2024n/an/a

-US$192m

Nov 30 2023n/an/a

-US$14m

Aug 31 2023n/an/a

US$6m

May 31 2023US$4mUS$756k

-US$52m

Feb 28 2023n/an/a

-US$37m

Nov 30 2022n/an/a

-US$33m

Aug 31 2022n/an/a

-US$33m

May 31 2022US$6mUS$736k

-US$27m

Feb 28 2022n/an/a

-US$40m

Nov 30 2021n/an/a

-US$38m

Aug 31 2021n/an/a

-US$34m

May 31 2021US$4mUS$720k

-US$32m

Feb 28 2021n/an/a

-US$169m

Nov 30 2020n/an/a

-US$171m

Aug 31 2020n/an/a

-US$170m

May 31 2020US$3mUS$716k

-US$167m

Feb 29 2020n/an/a

-US$7m

Nov 30 2019n/an/a

-US$6m

Aug 31 2019n/an/a

-US$7m

May 31 2019US$3mUS$687k

-US$11m

Feb 28 2019n/an/a

-US$34m

Nov 30 2018n/an/a

-US$16m

Aug 31 2018n/an/a

-US$12m

May 31 2018US$3mUS$643k

-US$6m

Compensatie versus markt: De totale vergoeding ($USD 5.01M ) Jim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jim Clemmer (60 yo)

8.6yrs

Tenure

US$5,005,971

Compensatie

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
James Clemmer
CEO, President & Director8.6yrsUS$5.01m1.17%
$ 3.2m
Stephen Trowbridge
Executive VP & CFO5.1yrsUS$1.82m0.26%
$ 715.1k
Chad Campbell
Senior VP and GM of Global Vascular Access & Oncology Business Unit8.5yrsUS$1.01m0.18%
$ 488.5k
Warren Nighan
Senior Vice President of Regulatory Affairs7.6yrsUS$995.08k0.11%
$ 308.3k
Laura Piccinini
Senior VP & GM of Endovascular Therapies and International3.4yrsUS$1.23m0.14%
$ 376.3k
Saleem Cheeks
Vice President of Communications4.8yrsgeen gegevensgeen gegevens
Benjamin Davis
Senior Vice President of Business Development & Strategy9.7yrsgeen gegevensgeen gegevens
Marna Bronfen-Moore
Senior Vice President of Human Resources5.2yrsgeen gegevensgeen gegevens
Kim Seabury
Senior Vice President of Information Technology13.2yrsgeen gegevensgeen gegevens
Juan Serna
Senior Vice President of Scientific & Clinical Affairs3.8yrsgeen gegevensgeen gegevens

6.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANGO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
James Clemmer
CEO, President & Director8.6yrsUS$5.01m1.17%
$ 3.2m
Jan Reed
Independent Director8yrsUS$225.11k0.21%
$ 587.1k
Wesley Johnson
Independent Director17.8yrsUS$234.81k0.30%
$ 805.6k
Howard Donnelly
Independent Non-Executive Chairman20.7yrsUS$262.01k0.37%
$ 1.0m
Eileen Auen
Independent Director8.8yrsUS$229.13k0.21%
$ 584.9k
Michael Dake
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Frank Veith
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Thomas Sos
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Stephen Kee
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
John Kaufman
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Jacob Cynamon
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Karen Licitra
Independent Director5.3yrsUS$224.51k0.18%
$ 488.9k

8.7yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANGO wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).